KIO-301

KIO-301 · Kiora Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for KIO-301, covering 2025-11-17 to 2025-11-20. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) [Phase 1, Phase 2]

See pricing